These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort study. Yen FS; Wei JC; Shih YH; Hung YT; Hsu TJ; Hsu CC; Hwu CM Diabetes Metab Syndr; 2024 Aug; 18(8):103099. PubMed ID: 39128378 [TBL] [Abstract][Full Text] [Related]
4. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels. D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425 [TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin. McCormick N; Yokose C; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; McCoy RG; Choi HK JAMA Intern Med; 2024 Jun; 184(6):650-660. PubMed ID: 38619822 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188 [TBL] [Abstract][Full Text] [Related]
7. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study. Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796 [TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study. Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989 [TBL] [Abstract][Full Text] [Related]
9. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180 [TBL] [Abstract][Full Text] [Related]
10. Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes. Franchi M; Pellegrini G; Avogaro A; Buzzetti G; Candido R; Cavaliere A; Consoli A; Marzona I; Mennini FS; Palcic S; Corrao G BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38802266 [TBL] [Abstract][Full Text] [Related]
11. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes. Paik JM; Tesfaye H; Curhan GC; Zakoul H; Wexler DJ; Patorno E JAMA Intern Med; 2024 Mar; 184(3):265-274. PubMed ID: 38285598 [TBL] [Abstract][Full Text] [Related]
12. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong. Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the Risk of Diabetic Retinopathy Between Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus in Japan: A Retrospective Analysis of Real-World Data. Koshizaka M; Tatsumi T; Kiyonaga F; Kosakai Y; Yoshinaga Y; Shintani-Tachi M Diabetes Ther; 2024 Nov; 15(11):2401-2416. PubMed ID: 39347896 [TBL] [Abstract][Full Text] [Related]
14. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. Garry EM; Buse JB; Lund JL; Pate V; Stürmer T Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561 [TBL] [Abstract][Full Text] [Related]
15. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study. Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857 [No Abstract] [Full Text] [Related]
16. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations. Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038 [No Abstract] [Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease. Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387 [TBL] [Abstract][Full Text] [Related]
18. Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors. Zerovnik S; Kos M; Locatelli I Acta Diabetol; 2022 Feb; 59(2):233-241. PubMed ID: 34609620 [TBL] [Abstract][Full Text] [Related]
19. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis. Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696 [TBL] [Abstract][Full Text] [Related]
20. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]